AbbVie Contract Manufacturing AbbVie Contract Manufacturing

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"HebaBiz Biotech","sponsor":"Johnpro Biotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HebaBiz Biotech's Anti-Cancer Drug Candidate Under Development Siroquine (JP001) has been Approved for IND Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"HebaBiz Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"R&D Milestone: HebaBiz Biotech's Application for Phase III clinical trial in China for Clevudine (L-FMAU), An Anti-Hepatitis B Virus Drug Candidate Under Development Has Been Approved","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals by HebaBiz Biotech

    Menu

    HebaBiz Biotech

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              HebaBiz Biotech

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              R&D Milestone: HebaBiz Biotech's Application for Phase III clinical trial in China for Clevudine (L-FMAU), An Anti-Hepatitis B Virus Drug Candidate Under Development Has Be...

              Details:

              L-FMAU (Clevudine) is a synthetic β-L nucleoside analogue introduced from Yale University and HebaBiz Biotech obtained its exclusive license for anti-hepatitis B virus in Greater China. L-FMAU as a new generation best-in-class anti-HBV new drug.

              Lead Product(s): Clevudine

              Therapeutic Area: Infections and Infectious Diseases Product Name: L-FMAU

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 15, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              HebaBiz Biotech

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              HebaBiz Biotech's Anti-Cancer Drug Candidate Under Development Siroquine (JP001) has been Approved for IND Clinical Trials

              Details:

              JP001 is a dual autophagy modulator being developed by HebaBiz Biotech, which can improve tumor microenvironment (TME) and increase tumor cells' sensitivity to chemoradiotherapy.

              Lead Product(s): Siroquine,Temozolomide

              Therapeutic Area: Oncology Product Name: JP001

              Highest Development Status: Phase II/ Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Johnpro Biotech

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 20, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Biopharma Group offers CDMO services with expertise in contract R&D for dried products & liquid formulations.
              Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.
              Post Enquiry
              POST ENQUIRY